Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CA9 synthetic peptide vaccine
- Development stage
- Unknown
- Lead developer
- Kurume University
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The CA9 synthetic peptide vaccine is a therapeutic cancer vaccine composed of three synthetic peptides (CA9p219-227, p288-296, and p323-331) derived from Carbonic Anhydrase IX (CA9). CA9 is a transmembrane protein and tumor-associated antigen that is highly and specifically expressed in clear cell renal cell carcinoma (RCC). The vaccine is designed for HLA-A24-positive patients and is administered subcutaneously with incomplete Freund's adjuvant. Its mechanism of action involves the induction of CA9-specific cytotoxic T lymphocytes (CTLs) and antibody responses to target and eliminate CA9-positive tumor cells. In a Phase I clinical trial, the vaccine was found to be well-tolerated and immunogenic in patients with cytokine-refractory metastatic RCC.
- Other names
- Carbonic anhydrase IX peptide vaccineCA9-derived peptide vaccineCA-9-derived peptide vaccineCA 9-derived peptide vaccine
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on CA9 synthetic peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CA9 synthetic peptide vaccine.